Entera Bio Ltd. (NASDAQ: ENTX) reported a net loss of $11.4 million, or $0.25 per share, for the year ended December 31 2025, a widening loss from the $9.5 million ($0.25 per share) recorded in 2024. Revenue for the year was $42,000, a sharp decline from $181,000 in 2024, reflecting the company’s limited commercial activity as it remains in the clinical‑stage development phase.
Research and development expenses rose to $6.0 million, up from $4.5 million in 2024, while general and administrative costs increased to $5.5 million from $5.1 million. Total operating expenses reached $11.5 million, a $1.9 million increase over the prior year, driven largely by the higher R&D spend needed to advance the EB613 program and prepare for a Phase 3 trial.
Cash and cash equivalents stood at $14.9 million as of December 31 2025, including $7.8 million in restricted cash earmarked for the OPKO collaboration. The unrestricted balance of $8.1 million is expected to support operations through the middle of the third quarter of 2026. With a quarterly burn rate of roughly $2.8 million, the company’s runway is limited to about three quarters unless additional capital is raised.
The company highlighted progress in its pipeline: the oral parathyroid hormone tablet EB613 completed Phase 2 and is preparing for a Phase 3 trial, while EB612 and EB618 are advancing toward IND filing. Miranda Toledano, CEO, said, "2025 was a landmark year for Entera, our EB613 program and for the osteoporosis community as a whole. We are eager to initiate our important phase 3 study for EB613 and thank the investigator and patient community for their enthusiasm to take part in this mission."
Investors reacted with a sharp sell‑off, focusing on the company’s limited cash runway and declining revenue. The announcement was met with concerns that the company’s high burn rate and minimal commercial income could pressure future financing and delay the launch of its first product.
Miranda Toledano added, "While current injectable anabolic or bone forming agents are accepted or accessed by a minority of osteoporosis patients in whom they should be used, our mission with EB613 is to democratize anabolic treatment. EB613 is being developed as the first oral bone building tablet so potentially, every woman and man can have the opportunity to protect their bones whether they are being treated with a primary care practitioner or a specialist." She also noted, "Throughout 2025, we also met every milestone relating to our pipeline and advanced each program with the utmost capital efficiency. Our N-Tab® oral peptide platform delivered differentiated preclinical data on LA-PTH, GLP-1/Glucagon and GLP-2 targets in partnership with OPKO Health, Inc. (OPKO)."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.